Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus

Keywords: infectious mononucleosis, Epstein-Barr virus, immune response, antiviral and immunomodulatory therapy

Abstract

The aim of the study was to evaluate the effectiveness of ribonucleic acid in the correction of immune disorders in patients with infectious mononucleosis (IM) caused by EBV.

Materials and methods. We examined 110 patients with a mean age of 23.3±4.2 years with IM, among whom women accounted for 52.7 % (n=58). The material for the study was the serum of patients obtained during the disease course. The set of tests of patients with IM included clinical and biochemical methods, enzyme-linked immunosorbent assay, polymerase chain reaction method, immunogram. Statistical processing of the obtained data was performed with “Statsoft Statistica v. 10.0 for Windows” using the methods of variation and correlation statistics.

Results. The obtained results analysis revealed changes in the system of cellular and humoral parts of the immune system and the diversity of the immune response in patients with IM. The progressive nature of changes in immune parameters indicated the formation of secondary cellular immune imbalance, activation of the humoral link, a change in the balance of immunoregulatory mediators towards Th2 cells. Significant changes in the cellular immune system were observed in the acute period and were characterized by the increase in the number of cells with killer activity, namely mature T-lymphocytes (CD3+), cytotoxic T-suppressor cells (CD8+), cells expressing the activation marker CD25+ (IL-2 receptor), and by the Th1/Th2 ratio increase. The appointment of combination therapy including ribonucleic acid was accompanied by immunomodulatory and antiviral effects, that was reflected in a more pronounced positive dynamics of immunological parameters, namely in strengthening the proliferative response, compared with the group of patients receiving only basic therapy.

Conclusion. The expediency of the combination therapy application: the drug Nuclex (ribonucleic acid) (250 mg) 2 capsules 3 times a day for 14 days and valacyclovir (500 mg) at a dose of 1000 mg (2 tablets) 3 times a day for 14 days, is justified for the correction of immune disorders in patients with IM caused by EBV.

Downloads

Download data is not yet available.

Author Biographies

Ksenia Pavlikova, V. N. Karazin Kharkiv National University

Department of Infectious Diseases and Clinical Immunology

School of Medicine

Tetiana Liadova, V. N. Karazin Kharkiv National University

Department of Infectious Diseases and Clinical Immunology

School of Medicine

Olga Volobueva, V. N. Karazin Kharkiv National University

Department of Infectious Diseases and Clinical Immunology

School of Medicine

Olesya Gololobova, V. N. Karazin Kharkiv National University

Department of Infectious Diseases and Clinical Immunology

School of Medicine

Nataliia Vinnikova, V. N. Karazin Kharkiv National University

Department of Infectious Diseases and Clinical Immunology

School of Medicine

References

Rostgaard, K., Balfour, H. H., Jarrett, R., Erikstrup, C., Pedersen, O., Ullum, H. et. al. (2019). Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLOS ONE, 14 (12), e0226436. doi: http://doi.org/10.1371/journal.pone.0226436
Kourieh, A., Gheit, T., Tommasino, M., Dalstein, V., Clifford, G. M. et. al. (2018). Prevalence of human herpesviruses infections in nonmalignant tonsils: The SPLIT study. Journal of Medical Virology, 91 (4), 687–697. doi: http://doi.org/10.1002/jmv.25338
Smatti, M. K., Al-Sadeq, D. W., Ali, N. H., Pintus, G., Abou-Saleh, H., Nasrallah, G. K. (2018). Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Frontiers in Oncology, 8. doi: http://doi.org/10.3389/fonc.2018.00211
Drozdova, N. F., Fazylov, V. K. (2018). Infectious mononucleosis caused by Epstein – Barr virus: clinical and pathogenic aspects (review). The Bulletin of Contemporary Clinical Medicine, 11 (3), 59–65. doi: http://doi.org/10.20969/vskm.2018.11(3).59-65
Balfour, H. H., Dunmire, S. K., Hogquist, K. A. (2015). Infectious mononucleosis. Clinical & Translational Immunology, 4 (2), e33. doi: http://doi.org/10.1038/cti.2015.1
Demina, O. I., Chebotareva, T. A., Mazankova, L. N., Tetova, V. B., Uchaeva, O. N. (2020). Clinical manifestations of infectious mononucleosis in primary or reactivated herpes virus infection. Russian Bulletin of Perinatology and Pediatrics, 65 (1), 37–44. doi: http://doi.org/10.21508/1027-4065-2020-65-1-37-44
Solomay, T. V., Semenenko, T. A., Karazhas, N. V., Rybalkina, T. N., Veselovsky, P. A., Pulnova, N. L. et. al. (2021). Features of change of immune status indicators in individuals with active and latent forms of herpes-virus infections. Perm Medical Journal, 38 (1), 46–63. doi: http://doi.org/10.17816/pmj38146-63
Sullivan, J. L. Clinical manifestations and treatment of Epstein-Barr virus infection. Available at: https://www.uptodate.com/contents/clinical-manifestations-and-treatment-of-epstein-barr-virus-infection Last accessed: 01.10.2021
Zhu, Z., Yin, S.-J., Kong, Z.-B., Li, H., Hu, L.-P., Zuo, S. et. al. (2017). Pancreatitis Combined with Epstein–Barr Virus-induced Infectious Mononucleosis. Chinese Medical Journal, 130 (16), 2001–2002. doi: http://doi.org/10.4103/0366-6999.211875
Bunchorntavakul, C., Reddy, K. R. (2020). Epstein-Barr Virus and Cytomegalovirus Infections of the Liver. Gastroenterology Clinics of North America, 49(2), 331–346. doi: http://doi.org/10.1016/j.gtc.2020.01.008
Dunmire, S. K., Verghese, P. S., Balfour, H. H. (2018). Primary Epstein-Barr virus infection. Journal of Clinical Virology, 102, 84–92. doi: http://doi.org/10.1016/j.jcv.2018.03.001
Barros, M. H. M., Vera-Lozada, G., Segges, P., Hassan, R., Niedobitek, G. (2019). Revisiting the Tissue Microenvironment of Infectious Mononucleosis: Identification of EBV Infection in T Cells and Deep Characterization of Immune Profiles. Frontiers in Immunology, 10. doi: http://doi.org/10.3389/fimmu.2019.00146
Kim, H.-J., Ko, Y. H., Kim, J. E., Lee, S.-S., Lee, H. et. al. (2017). Epstein-Barr Virus–Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification. Journal of Pathology and Translational Medicine, 51 (4), 352–358. doi: http://doi.org/10.4132/jptm.2017.03.15
Fugl, A., Andersen, C. L. (2019). Epstein-Barr virus and its association with disease – a review of relevance to general practice. BMC Family Practice, 20 (1). doi: http://doi.org/10.1186/s12875-019-0954-3
Kennedy, S. (2020). Herpes virus infections and psychoneuroimmunology. Psychoneuroimmunology, stress, and infection. CRC Press, 231–242. doi: http://doi.org/10.1201/9780367812522-12
Correia, S., Bridges, R., Wegner, F., Venturini, C., Palser, A., Middeldorp, J. M. et. al. (2018). Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases. Journal of Virology, 92 (22). doi: http://doi.org/10.1128/jvi.01132-18
Bakkalci, D., Jia, Y., Winter, J. R., Lewis, J. E., Taylor, G. S., Stagg, H. R. (2020). Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. Journal of Global Health, 10 (1). doi: http://doi.org/10.7189/jogh.10.010405
Liadova, T. I., Pavlikova, K. V. (2019). The Research of Dynamics of Immune Responsibility Indicators in Patients with Epstein–Barr Virus (EBV) Infections. Journal of V.N. Karazin Kharkiv National University, series «Medicine» 39 (1), 39–48. doi: http://doi.org/10.26565/2313-6693-2019-38-05
Pagano, J., Whitehurst, C., Andrei, G. (2018). Antiviral Drugs for EBV. Cancers, 10 (6), 197. doi: http://doi.org/10.3390/cancers10060197
Siliézar, M. M., Muñoz, C. C., Solano-Iturri, J. D., Ortega-Comunian, L., Mollejo, M., Montes-Moreno, S., Piris, M. A. (2018). Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis. American Journal of Clinical Pathology, 150 (4), 310–317. doi: http://doi.org/10.1093/ajcp/aqy056
Zhang, L., Zhou, P., Meng, Z., Pang, C., Gong, L., Zhang, Q. et. al. (2018). Infectious mononucleosis and hepatic function. Experimental and therapeutic medicine, 15 (3), 2901–2909. doi: http://doi.org/10.3892/etm.2018.5736
Hu, J., Zhang, X., Yu, G., Cai, H., Gu, J., Hu, M. et. al. (2019). Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis. BMC Gastroenterology, 19 (1). doi: http://doi.org/10.1186/s12876-019-1021-1
Yurko, K., Kozko, V., Merkulova, N., Mohylenets, O., Khrystenko, N. (2020). Clinical and laboratory characteristics of infectious mononucleosis caused by Epstein-Barr, effectiveness of treatment methods. Norwegian Journal of Development of the International Science, 39, 50–52. Available at: https://cyberleninka.ru/article/n/clinical-and-laboratory-characteristics-of-infectious-mononucleosis-caused-by-epstein-barr-effectiveness-of-treatment-methods
Stepanenko, Y., Nikolaiev, R., Tkachuk, Z. (2019). Spectral studies of oligoribonucleotide-based drugs. Proceedings of 5th International Electronic Conference on Medicinal Chemistry. doi: http://doi.org/10.3390/ecmc2019-06326
Gil-Rodríguez, A. M., Garcia-Gutierrez, E. (2021). Antimicrobial mechanisms and applications of yeasts. Advances in Applied Microbiology. Elsevier Inc., 37–72. doi: http://doi.org/10.1016/bs.aambs.2020.11.002

👁 65
⬇ 56
Published
2021-11-30
How to Cite
Pavlikova, K., Liadova, T., Volobueva, O., Gololobova, O., & Vinnikova, N. (2021). Clinical and immunological efficiency of different therapy regimens in patients with infectious mononucleosis caused by Epstein-Barr virus. EUREKA: Health Sciences, (6), 3-9. https://doi.org/10.21303/2504-5679.2021.002177
Section
Medicine and Dentistry